Hansoh Pharma Hosts 2022 Harmony Global Summit Highlighting Novel Glucose-Lowering Therapy Fulaimei

China Economic Net, April 26 (Reporter Guowang Zhu) — On April 23, the "Joining Hands for Progress, Harmony, and Beauty — 2022 Harmony and Beauty Global High-Level Forum," hosted by Hansoh Pharma, was successfully held. The meeting invited Professor Zhao Jiajun, Chairman of the Chinese Society of Endocrinology (CSE); Professor Wang Weiqing, President-Elect of CSE; Professor Guo Lixin, President-Elect of the Chinese Diabetes Society (CDS); Professor Yang Wenying, principal investigator (PI) of the Phase III clinical trial of Fulamore at China-Japan Friendship Hospital; Professor Hertzel C. Gerstein from Canada; and other global academic experts in the field of diabetes to gather and discuss topics such as "GLP-1 Treatment Options for Chinese T2DM Patients and the Balanced Benefits of Fulamore." Since its launch three years ago, Fulamore has been recognized by the attending experts for its excellent clinical efficacy, safety, and innovative advantages.

As China's first self-innovated long-acting GLP-1 class hypoglycemic drug, Fulaimei (Hansoh Pharma's product) has undertaken the national "Major New Drug Creation Science and Technology Major Project," received two national invention patents, and obtained patents in multiple countries and regions including Europe, the US, and Japan. In May 2021, Fulaimei was included in the "2020 Edition CDS Guidelines" by the Diabetes Society of the Chinese Medical Association (CDS). Data shows that GLP-1RA can effectively lower blood sugar, partially restore pancreatic β-cell function, and also has multiple effects such as reducing body weight, improving lipid profiles, and protecting kidney function.

At the forum, Professor Wang Weiqing from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, pointed out that the development of Fulai Mei is a milestone in the advancement of diabetes drugs in China, benefiting a wider patient population.

Professor Yang Wenying stated that Chinese T2DM patients are more suitable for Fulaimei GLP-1 treatment, which offers long-acting rapid blood sugar reduction, proven efficacy, low adverse reactions, and can achieve weight loss as needed while balancing blood sugar control and fluctuations, fully meeting the clinical needs of Chinese T2DM patients for GLP-1 treatment.

　　Lower frequency of administration, higher safety

Traditional hypoglycemic drugs, while intensively lowering blood sugar, often increase the risk of hypoglycemia; factors such as high-frequency dosing, adverse drug reactions, and the complexity of treatment regimens often lead to poor medication adherence. This not only affects patients' health and quality of life but also causes them to lose confidence in treatment, trapping them in a vicious cycle of disease management. According to reports, Fulaimei (孚来美) has demonstrated excellent safety, significantly reducing the incidence of adverse reactions while controlling blood glucose. Since the glucose-lowering mechanism of GLP-1RA is glucose concentration-dependent, the incidence of hypoglycemic events is significantly lower compared to traditional hypoglycemic drugs, whether used as monotherapy or in combination with metformin (≤2.2%).

Professor Guan Xiaohong from the General Hospital of the People's Liberation Army Air Force believes that pegloptin, which adopts the third-generation PEG modification technology, features rapid onset and fewer adverse reactions.

Canadian scholar, Professor Hertzel C. Gerstein from McMaster University, emphasized that Exendin-4 based GLP-1RA can also provide cardiovascular benefits. Fulaimi? meets the "dual exposure" requirement and has characteristics that benefit the cardiovascular system.

　Good Medicines Benefit Patients, Continuously Enhancing Accessibility

It is worth mentioning that the polyethylene glycol losenatide injection pen is easy to operate and can be used multiple times, providing convenience for patients requiring long-term medication. As a Class 1 new drug in China, Fulaimei has provided numerous doctors and patients with effective, safe, and convenient blood sugar control strategies and treatment options since its launch three years ago. It was approved for marketing in China in May 2019 and included in the National Medical Insurance Drug List by the end of December 2020.

Lü Aifeng, Executive Director of Hansoh Pharmaceutical Group Company Limited, stated: "As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has always been committed to addressing unmet clinical needs in the treatment of major diseases with high incidence in China. Fulamei is the world's first once-weekly polyethylene glycolated GLP-1 receptor agonist (GLP-1RA). Since its launch, it has helped hundreds of thousands of diabetes patients achieve glycemic control and multiple benefits due to its long-acting, superior efficacy, and safety advantages. In the future, Hansoh Pharma will actively fulfill its commitment to Chinese patients with diabetes and other serious chronic diseases by bringing globally leading innovative diagnostic technologies and therapeutic drugs to more patients, fully supporting the early realization of the grand blueprint of 'Healthy China 2030'."